Table 2.
Serological response | |||||||
---|---|---|---|---|---|---|---|
Variable | Category | Positive | Negative | Total | P | Odds ratio | 95% CI |
n (%) | n (%) | ||||||
All patients | 41 (23.8) | 131 (76.2) | 172 (100) | ||||
Age at time of vaccination (y) | ≤65 | 12 (36.4) | 21 (63.6) | 33 (19.2) | .060 | 2.2 | 0.9-5.3 |
>65 | 29 (20.9) | 110 (79.1) | 139 (80.8) | ||||
Sex | Female | 14 (27.5) | 37 (72.5) | 51 (29.7) | .470 | 1.3 | 0.6-3.0 |
Male | 27 (22.3) | 94 (77.7) | 121 (70.3) | ||||
Treatment status | Treatment-naïve | 16 (40.0) | 24 (60.0) | 40 (23.3) | <.001 | 4.9 | 1.9-12.9 |
On-therapy | 12 (12.0) | 88 (88.0) | 100 (58.1) | ||||
Off-therapy | 13 (40.6) | 19 (59.4) | 32 (18.6) | 5.0 | 1.8-14.1 | ||
Treatment status | Lack of active therapy | 29 (40.3) | 43 (59.7) | 72 (41.9) | <.001 | 5.0 | 2.2-11.5 |
On-therapy | 12 (12.0) | 88 (88.0) | 100 (58.1) | ||||
Binet stage | A | 16 (40.0) | 24 (60.0) | 40 (72.7) | .360 | 1.8 | 0.4-8.4 |
B or C | 4 (26.7) | 11 (73.3) | 15 (27.3) | ||||
IGHV mutational status | Mutated | 9 (22.0) | 32 (78.0) | 41 (36.6) | .778 | 1.2 | 0.4-3.2 |
Unmutated | 14 (19.7) | 57 (80.3) | 71 (63.4) | ||||
FISH | Normal | 8 (24.2) | 25 (75.8) | 33 (22.9) | .910 | ||
del(13q) | 8 (21.1) | 30 (78.9) | 38 (26.4) | 1.2 | 0.3-4.2 | ||
Trisomy 12 | 5 (21.7) | 18 (78.3) | 23 (16.0) | 1.2 | 0.3-4.9 | ||
del(11q) | 4 (14.3) | 24 (85.7) | 28 (19.4) | 1.9 | 0.4-8.9 | ||
del(17p) | 5 (22.7) | 17 (77.2) | 22 (15.3) | 1.1 | 0.3-4.7 | ||
Treatment protocol | BTK inhibitor | 9 (15.3) | 50 (84.7) | 59 (59.0) | .499 | 2.2 | 0.6-10.4 |
Venetoclax ± anti-CD20 antibody | 3 (7.7) | 36 (92.3) | 39 (39.0) | ||||
Others | 0 (0.0) | 2 (100) | 2 (2.0) | *NC | |||
Anti-CD20 (last treatment) | ≥12 mo | 15 (22.7) | 51 (77.3) | 66 (70.2) | .033 | 7.9 | 1.25-48.9 |
Within <12 mo | 1 (3.6) | 27 (96.4) | 28 (29.8) | ||||
Serum IgG level (mg/dL) | ≥550 | 28 (26.9) | 76 (73.1) | 104 (68.4) | .047 | 2.58 | 1.02-7.29 |
<550 | 6 (12.5) | 42 (87.5) | 48 (31.6) | ||||
Serum IgM level (mg/dL) | ≥40 | 5 (15.6) | 27 (84.4) | 32 (21.2) | .337 | 0.6 | 0.2-1.9 |
<40 | 28 (23.5) | 91 (76.5) | 119 (78.8) | ||||
Serum IgA level (mg/dL) | ≥80 | 25 (38.5) | 40 (61.5) | 65 (42.8) | <.001 | 5.4 | 2.2-13.9 |
<80 | 9 (10.3) | 78 (89.7) | 87 (57.2) |
Due to a limited number of patients who received other treatments, an odds ratio was not calculated (NC).